Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1822-2026

Brand Name: Cellex Photopheresis System Product Name: CELLEX Photopheresis Kit Recall

Brand Name: Cellex Photopheresis System Product Name: CELLEX Photopheresis Kit Model/Catalog Number: CLXUSA Software Version: Not Applicable Product Description: THERAKOS Photopheresis or extracorporeal photopheresis (ECP) is a photoimmune therapy where leukocytes are separated from whole blood via apheresis, combined with a photoactive drug (8-methoxypsoralen) and then exposed to ultraviolet A (UVA) light. All blood components, including the treated leukocytes, are returned to the patient. THERAKOS¿ Photopheresis utilizes the THERAKOS CELLEX System to combine cell separation and photoactivation into a single, closed and sterile circuit. The THERAKOS CELLEX Photopheresis System collects the buffy coat (leukocyte-enriched blood) from the patient in a discontinuous flow process and intermittently returns the remaining plasma and erythrocytes to the patient. The buffy coat is passed through the photoactivation module where the drug is activated with a precise amount of UVA light determined by the characteristics of the individual patient s buffy coat. After photoactivation, the buffy coat is immediately returned to the patient s bloodstream. Component: Not Applicable

FDA recall Class II

Ongoing

FDA lists this Class II recall for Brand Name: Cellex Photopheresis System Product Name: CELLEX Photopheresis Kit. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1822-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
May 16, 2025
FDA report date
Apr 22, 2026
Quantity in commerce
11,499 units
Distribution
See key details
FDA cause
Process control

What is being recalled?

Brand Name: Cellex Photopheresis System Product Name: CELLEX Photopheresis Kit Model/Catalog Number: CLXUSA Software Version: Not Applicable Product Description: THERAKOS Photopheresis or extracorporeal photopheresis (ECP) is a photoimmune therapy where leukocytes are separated from whole blood via apheresis, combined with a photoactive drug (8-methoxypsoralen) and then exposed to ultraviolet A (UVA) light. All blood components, including the treated leukocytes, are returned to the patient. THERAKOS Photopheresis utilizes the THERAKOS CELLEX System to combine cell separation and photoactivation into a single, closed and sterile circuit. The THERAKOS CELLEX Photopheresis System collects the buffy coat (leukocyte-enriched blood) from the patient in a discontinuous flow process and intermittently returns the remaining plasma and erythrocytes to the patient. The buffy coat is passed through the photoactivation module where the drug is activated with a precise amount of UVA light determined by the characteristics of the individual patient s buffy coat. After photoactivation, the buffy coat is immediately returned to the patient s bloodstream. Component: Not Applicable

Affected model & UDI checker

Search the exact identifiers published for Z-1822-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
Not specifiedBrand Name: Cellex Photopheresis System Product Name: CELLEX Photopheresis KitCheck source notice20705030200003
FDA code information

Model/Catalog Number: CLXUSA; UDI-DI: 20705030200003; Lot Numbers: N301, N339, N340, N341, N342, N343, N344, N345, N346, N347; P302, P303, P304, P305, P306, P307, P308, P309, P310, P311, P312, P313, P314, P319, P320.

View the original FDA recall notice

Why was this product recalled?

Increased difficulty in installing the centrifuge bowl onto the centrifuge bowl holder. Improper installation may cause the centrifuge bowl to dislodge, resulting in a broken bowl during the prime cycle or treatment phase, leading to a delay in patient treatment and blood loss.

What actions did THERAKOS DEVELOPMENT LIMITED take?

On May 28, 2025 MEDICAL DEVICE RECALL letters were sent to customers. Actions to be taken: Determine if your facility has any of the impacted lots listed. 1. If you have received any of the kit lot numbers listed, quarantine the product and contact our Customer Care Team at 1-833-223-4ECP (1-833-223-4327) to receive instructions on how to return the affected product. 2. To report a complaint or adverse event or if you have any other questions related to the recall, please call the Customer Care Team at 1-833-223-4ECP (1-833-223-4327). Always follow the instructions for use as detailed in the Operator s Manual when installing the THERAKOS CELLEX Photopheresis System Procedural Kits. Ensuring the correct installation of the Procedural Kits is critical for system performance and avoiding treatment interruptions. A MEDICAL DEVICE RECALL notification dated 6/23/26 was communicated to additional consignees due to the expansion of this recall to include additional lots. Consignees are to quarantine affected product and coordinate with Therakos return of devices.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology